Nutrition in Patients with Inflammatory Bowel Diseases: A Narrative Review

Abstract

Inflammatory bowel diseases (IBD) affect the gastrointestinal tract: they include Crohn’s disease (CD) and ulcerative colitis (UC). Each has a different phenotypic spectrum, characterized by gastrointestinal and extra-intestinal manifestations. People living with IBD are very interested in diet, but little is known about the impact of diet on these patients; no guidelines are available yet. In this review, we analyze the dietary patterns of patients with IBD and the approach to the choices of foods both in adults and pediatric patients. Very often, IBD patients report an intentional avoidance of gluten to manage the disease; furthermore, a proportion of IBD patients believe that dairy products worsen their symptoms and that avoidance may help the disease. They have a low compliance with the Mediterranean Diet, which is considered to have potential benefits but is little used in practice. In conclusion, the review underscores the pivotal role of nutritional counselling in IBD patients, and the importance of future clinical studies to evaluate the beneficial effects of dietary recommendations in the management of IBD.

Inflammatory bowel disease in Korea: epidemiology and pathophysiology

“…Many investigators have postulated that a Western diet may contribute to the unfavorable results. However, no well-established guideline for any specific (helpful) diet is available [62]. Welldesigned clinical trials are needed to confirm whether dietary therapy effectively induces remission [63,64].…”

"Out of the box� new therapeutic strategies for Crohn�s disease: moving beyond biologics

“…In general, IBD patients have low compliance with strict MD in countries outside the Mediterranean. Despite its documented benefits for health and modulating inflammation, MD is still rarely used as treatment in IBD in many countries (73).…”

Ethanolic Extract from Pteris wallichiana Alleviates DSS-Induced Intestinal Inflammation and Intestinal Barrier Dysfunction by Inhibiting the TLR4/NF-κB Pathway and Regulating Tight Junction Proteins

“…UC had been classified as a refractory disease by the World Health Organization due to its complicated pathology, diagnosis, and treatment [ 2 ]. In many countries, the incidence of UC increases every year, and its symptoms can be repeated for several months or years, which reduces the life quality of patients [ 3 ]. At present, the main clinical drugs of UC are adrenal cortex hormones, salicylic acids, immunosuppressive agents, and anti-inflammatory drugs.…”